slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 45,721-45,750
Pages 10,126
Rows per page 30
Component
45,721-45,750 of 303,780
60
The slide uses a traffic-light color coding system to highlight the superior profile of EXS4318.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
61
The slide uses a process-flow layout with icons representing each stage.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
62
The background features a 3D molecular visualization, likely representing the LSD1 protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
63
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
64
The slide uses a hub-and-spoke diagram to illustrate the interaction of LSD1 with various protein complexes, receptors, and RNAs.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
65
The slide uses a biological process diagram to explain the mechanism of action for a drug candidate ('539).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
66
The slide uses a process flow diagram to explain the therapeutic mechanism.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
67
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
68
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
69
The table uses a traffic-light color coding system to indicate performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
70
The slide outlines a specific workflow involving generative design, ML, and active learning.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
71
The chart uses a scatter plot to visualize the Pareto front in drug discovery, highlighting the selection of compounds 1 and 2.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
72
The slide uses two distinct chart types (dot plot and line chart with error bars) to illustrate the safety profile of the drug candidate '539.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
73
Data shows heterogeneity of response across different patient samples, categorized by differentiation level.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
74
The slide uses a heatmap to visualize synergy (green = yes, light green = no) across 6 drug combinations and 14 patient samples.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
75
Includes statistical significance markers (asterisks) and safety observation regarding body weight.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
76
Uses Bliss Independence Model for synergy calculation. Includes a heatmap of synergy across subtypes and dose-response curves for two specific models (DMS79 and H345).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction2 hits
77
The heatmap displays AUC values for 16 patient samples across three treatments.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
78
The slide uses a two-column layout to contrast PK and Toxicology findings.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
79
MIDD = Model-informed Drug DevelopmentExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
81
The slide uses a three-column layout to summarize the value proposition of a drug candidate.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
82
The slide uses a biological pathway diagram to illustrate the mechanism of action.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
83
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
84
The slide uses a biological mechanism argument to establish a safety/efficacy advantage for the drug candidate '565.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
85
The slide uses a heatmap-style table to visualize performance against criteria, with a specific focus on UGT1A1 inhibition risk.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
86
The slide uses a linear process flow to explain a complex drug discovery workflow.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
87
The slide highlights the application of computational chemistry (molecular dynamics) to drug discovery, specifically focusing on binding site analysis.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
88
The slide presents preclinical efficacy data for a MALT1 inhibitor ('565) in combination with Ibrutinib.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
89
The slide uses dose-response curves to show IC50 and selectivity.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits
90
The table uses a heatmap-style color coding (red/green) to indicate risk levels.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 2 hits